Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib plus pembrolizumab maintenance versus placebo plus pembrolizumab in advanced non-small cell lung cancer
2020-002202-20Phase 3Unknown
- Sponsor
- GSK
- Start
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Niraparib plus pembrolizumab with Placebo plus pembrolizumab (2 arms). Primary endpoints: Progression-free survival, Overall survival and 1 more. Status: unknown.
02
Drugs
niraparibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2020-002202-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002202-20.